SCHEMBL1920707

SCHEMBL1920707

C[N+](C)(C)c1cccc(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 10/20 1.00
TSHR P16473 3/20 0.63
OPRM1 P35372 1/20 0.63
BLM P54132 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
ALDH1A1 P00352 2/20 0.52
LMNA P02545 2/20 0.52
CYP3A4 P08684 2/20 0.52
CA12 O43570 1/20 0.52
CA2 P00918 1/20 0.52
CA5A P35218 1/20 0.52
CA9 Q16790 1/20 0.52
HSD17B10 Q99714 1/20 0.52
CA14 Q9ULX7 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
APOBEC3A P31941 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
CHRM2 P08172 1/20 0.45
CHRM1 P11229 1/20 0.45
CHRM3 P20309 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL29488102 0.98 ACHE (0.95) ACHETSHROPRM1BLMSMN1; SMN2
Hydrochloric Acid SCHEMBL30945416 0.98 ACHE (0.95) ACHETSHROPRM1BLMSMN1; SMN2
Hydrochloric Acid SCHEMBL28469713 0.98 ACHE (0.95) ACHETSHROPRM1BLMSMN1; SMN2
Water SCHEMBL11727004 0.98 ACHE (0.95) ACHETSHROPRM1BLMSMN1; SMN2
Dimethylcarbate SCHEMBL4413046 0.83 ACHE (0.69) ACHETSHROPRM1BLMSMN1; SMN2
Dimethylcarbate SCHEMBL4413044 0.82 ACHE (0.67) ACHETSHROPRM1BLMSMN1; SMN2
SCHEMBL26628889 0.81 ACHE (0.67) ACHETSHROPRM1BLMSMN1; SMN2
Edrophonium SCHEMBL8009388 0.78 ACHE (1.00) ACHETSHROPRM1BLMSMN1; SMN2
Edrophonium SCHEMBL29627074 0.78 ACHE (1.00) ACHETSHROPRM1BLMSMN1; SMN2
Edrophonium SCHEMBL34790 0.78 ACHE (1.00) ACHETSHROPRM1BLMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741264-B2 Self-sterilizing products MOLTENI THERAPEUTICS S.R.L. (IT) 2014-06-03 US claimed
EP-1904109-B1 SELF-STERILIZING PRODUCTS MOLTENI & C (IT) 2013-04-03 EP claimed
EP-1904060-B1 USE OF PHTHALOCYANINE DERIVATES FOR THE NON-PHOTODYNAMIC TREATMENT OF DISEASES MOLTENI & C (IT) 2011-06-01 EP claimed
US-20090130049-A1 Self-Sterilizing Products L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.P.A. (IT) 2009-05-21 US claimed
EP-1164135-B1 Substituted metal-phthalocyanines, their preparation and the use thereof MOLTENI & C (IT) 2004-02-18 EP claimed
US-20230149294-A1 READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE SLAYBACK PHARMA LLC (US) 2023-05-18 US disclosed
US-20150126703-A1 CATALYZED POLYMERIZATION OF CYCLIC ESTERS AND CYCLIC CARBONATES UNIVERSITE DE MONS (BE) 2015-05-07 US disclosed
US-20150126703-A1 CATALYZED POLYMERIZATION OF CYCLIC ESTERS AND CYCLIC CARBONATES UNIVERSITE DE MONS (BE) 2015-05-07 US disclosed
US-8741264-B2 Self-sterilizing products MOLTENI THERAPEUTICS S.R.L. (IT) 2014-06-03 US disclosed
EP-1904109-B1 SELF-STERILIZING PRODUCTS MOLTENI & C (IT) 2013-04-03 EP disclosed
WO-2011012698-A2 PHTHALOCYANINE DERIVATIVE CONSISTING OF A MIXTURE OF 4 ISOMERS L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.P.A. (IT) 2011-02-03 WO disclosed
US-20090130049-A1 Self-Sterilizing Products L. MOLTENI & C. DEI FRATELLI ALITTI SOCIETA' DI ESERCIZIO S.P.A. (IT) 2009-05-21 US disclosed
US-7422694-B2 Process for the microbiological decontamination of water by means of photosensitive agents SALBERT CO., LTD. (CN) 2008-09-09 US disclosed
US-4134792-A Specific binding assay with an enzyme modulator as a labeling substance MILES LABORATORIES, INC. (US) 1979-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149294-A1 READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE CHRNA5, CHRNB4, CHRNB1 ACHE 25/4885TSHR 278/4885OPRM1 223/4885
US-20090130049-A1 Self-Sterilizing Products NASP, ZP1, SPAG5 ACHE 4720/4885TSHR 4384/4885OPRM1 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.